Back to Search
Start Over
Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function
- Source :
- Journal of Cystic Fibrosis, Journal of Cystic Fibrosis, 2020, 20 (2), pp.220-227. ⟨10.1016/j.jcf.2020.06.012⟩, Journal of Cystic Fibrosis, Elsevier, 2020, ⟨10.1016/j.jcf.2020.06.012⟩
- Publication Year :
- 2020
-
Abstract
- International audience; Background: Phase 3 trials have demonstrated the safety and efficacy of lumacaftor-ivacaftor (LUMA-IVA) in patients with cystic fibrosis (CF) homozygous for the Phe508del CFTR mutation and percent predicted forced expiratory volume in 1 s (ppFEV1) between 40 and 90. Marketing authorizations have been granted for patients at all levels of ppFEV1.Methods: To evaluate the safety and effectiveness of LUMA-IVA over the first year of treatment in patients with ppFEV1
- Subjects :
- 0301 basic medicine
Pulmonary and Respiratory Medicine
Adult
Male
medicine.medical_specialty
Adolescent
Cystic Fibrosis
[SDV]Life Sciences [q-bio]
Aminopyridines
Quinolones
Aminophenols
Cystic fibrosis
Ivacaftor
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Internal medicine
medicine
Humans
In patient
Benzodioxoles
Chloride Channel Agonists
Lung function
ComputingMilieux_MISCELLANEOUS
business.industry
Lumacaftor
Authorization
medicine.disease
3. Good health
Respiratory Function Tests
Drug Combinations
030104 developmental biology
Cftr mutation
030228 respiratory system
chemistry
Pediatrics, Perinatology and Child Health
Disease Progression
Female
France
business
medicine.drug
Subjects
Details
- ISSN :
- 18735010 and 15691993
- Volume :
- 20
- Issue :
- 2
- Database :
- OpenAIRE
- Journal :
- Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
- Accession number :
- edsair.doi.dedup.....c90b3ae031d7c4ab8192a84adc836406
- Full Text :
- https://doi.org/10.1016/j.jcf.2020.06.012⟩